AC Immune SA ACIU 深 沪
交易中 10-29 09:46:40 美东时间
3.52
0.000
0.00%
华盛通- 最 高3.52
- 今 开3.52
- 成交量 1653股
- 最 低 3.52
- 昨 收 3.52
- 总市值 3.56亿
- 52周最高 3.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.4299
- 委 比 -71.51%
- 总股本 1.01亿
- 历史最高 17.40
- 量 比 1.41
- 振 幅 0.00%
- 历史最低 1.4299
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
AC Immune appoints Catherine Mummery as Chair of its Clinical Advisory Board (CAB). Prof. Mummery, a leading neurologist specializing in dementia trials, brings extensive expertise in developing innovative therapies targeting neurodegenerative diseases. She has led numerous early-stage trials, including AC Immune's anti-pTau immunotherapy ACI-35.030. Mummery's appointment strengthens AC Immune's pipeline of precision prevention candidates, includ...
10-28 11:00
AC Immune's Preclinical Data On Brain Positron Emission Tomography Tracers For Imaging Tdp-43 Pathology ACI-19626 Candidate Demonstrates High Specificity, Selectivity For Target
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the publication in Nature Communications of preclinical data on its
10-24 20:55
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
AC Immune's ACI-19626, a novel TDP-43 PET tracer, has been characterized in *Nature Communications* and shows promise for precision medicine in neurodegenerative diseases like ALS, FTD, and LATE. TDP-43 aggregates are a key pathological marker in these conditions, complicating diagnosis. ACI-19626 demonstrates high specificity and sensitivity for detecting TDP-43 pathology, with favorable pharmacokinetic properties for brain PET imaging. The trac...
10-24 12:50
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
AC Immune announced the publication of Phase 1b/2a trial results for ACI-35.030, an active immunotherapy targeting pathological Tau in early Alzheimer's disease. The trial demonstrated ACI-35.030's ability to induce rapid, potent, and sustained antibody responses against pTau and ePHF, with no clinically relevant safety issues. ACI-35.030 is now advancing to a Phase 2b ReTain trial, enrolling approximately 500 participants with preclinical AD, to...
09-25 11:00
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
09-08 18:04
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
AC Immune锐化其研发管线聚焦点，通过提升运营效率延长现金流跑道。公司高管团队的战略性评估促使裁员约30%，并将资源集中在阿尔茨海默病与帕金森病的晚阶段免疫疗法开发，以及能够实现细胞内靶向的高价值候选药物。公司现金流截至2025年6月30日为1.271亿瑞士法郎，运营资金可支持至2027年第三季度。AC Immune计划在年底前完成裁员，并提供解雇补偿与就业支持。
09-04 07:45
AC Immune Q2 EPS $(0.21) Misses $(0.17) Estimate, Sales $1.54M Miss $1.98M Estimate
AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 20.69 percent. This is a 16 percent increase over losses of $(0.25) per share from the same
08-05 19:25
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune reported strong progress in its neurodegenerative disease pipeline and a solid cash position of CHF 127.1 million. The company highlighted advancements in three active immunotherapies, including ACI-7104.056 in Parkinson's disease, demonstrating strong immunogenicity and safety. The Phase 2 ABATE trial for ACI-24.060 in Alzheimer's disease is on track to reach its 12-month treatment timepoint by year-end. Additionally, the small molecul...
08-05 11:00
AC Immune SA Announces Leadership Changes in Development Team
An announcement from AC Immune SA ( ($ACIU) ) is now available. On June 11, 202...
06-12 04:27
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.
05-17 01:32
